Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A, -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (3037)	7/19/2010 11:07:39 AM
From: Jibacoa	Respond to of 3722

ARNA opened with a small UG and was up 12.93% at its H at 938am.<g> It is still up 7.51% at present. Volume is already above its ADV bigcharts.marketwatch.com The stock needs to close above its July 15 H of $5.72 bigcharts.marketwatch.com ARNA is still benefiting from the fact that an FDA panel refused to recommend the approve of VVUS' Qnexa because of safety concerns.<g> ARNA's lorcaserin which is also up for FDA approval, supposedly has a more favorable safety profile than Qnexa The ACTAY is $5.86 ARNA has been trimming its losses in the last 4Qs. I will keep a TT at $10 pending further developments <g> bigcharts.marketwatch.com Bernard